Prusogliptin

DB20606InvestigationalSmall molecule

Prusogliptin is a small molecule drug. The usage of the INN stem '-gliptin' in the name indicates that Prusogliptin is a dipeptidyl aminopeptidase-IV inhibitor. Prusogliptin is under investigation in clinical... Prusogliptin is under investigation in clinical trial NCT07026968 (A Study of Prusogliptin Tablets Combined With Dapagliflozin Tablets and Metformin Hydrochloride Extended Release Tablets in Type 2 Diabetes).

Mechanism: Pharmacologically active on Dipeptidyl peptidase 4
Curator reviewed
Formula / weight: C₁₆H₂₅FN₄O₂ · 324.4 g/mol (avg)
Code names: DBPR-108

Resolves to

Compound

UNIIE329HG23ZTCAS1186426-66-3ChEMBLCHEMBL1082462ChEBI749157PubChem44201003

Structure

InChIKeyVQKSCYBKUIDZEI-STQMWFEESA-NSMILESCC(C)(CC(=O)N1CCCC1)NCC(=O)N1C[C@@H](F)C[C@H]1C#N

Targets

P27487DPP4

What you can answer from here — as of September 23, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

7Clinical trialsPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with Prusogliptin, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account